Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been given an average rating of “Buy” by the nineteen brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $163.93.
A number of equities analysts have weighed in on the stock. Citigroup decreased their price objective on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, May 23rd. Raymond James increased their price objective on shares of Alexion Pharmaceuticals from $164.00 to $168.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. started coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, July 31st. They issued an “overweight” rating and a $172.00 target price for the company. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a report on Thursday, April 25th. Finally, Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 24th.
Alexion Pharmaceuticals stock traded up $2.78 during mid-day trading on Thursday, hitting $111.47. The company’s stock had a trading volume of 1,167,499 shares, compared to its average volume of 1,612,324. The firm has a market cap of $24.99 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 1.05 and a beta of 1.65. Alexion Pharmaceuticals has a 1 year low of $92.56 and a 1 year high of $141.86. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average price of $120.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the business posted $2.07 earnings per share. As a group, analysts predict that Alexion Pharmaceuticals will post 9 earnings per share for the current fiscal year.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total value of $15,625,063.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the transaction, the executive vice president now owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 428,567 shares of company stock valued at $53,420,869. Corporate insiders own 4.08% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Investors Research Corp bought a new stake in shares of Alexion Pharmaceuticals in the first quarter worth $27,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Alexion Pharmaceuticals in the second quarter worth $28,000. Redhawk Wealth Advisors Inc. bought a new stake in shares of Alexion Pharmaceuticals in the second quarter worth $29,000. Ossiam bought a new stake in shares of Alexion Pharmaceuticals in the second quarter worth $32,000. Finally, Thor Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals in the first quarter worth $34,000. 93.77% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: What does earnings per share mean?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.